Single/ Multiple-Dose Study of E6007 in Healthy Japanese Male Subjects

Overview

This is a single-center, placebo-controlled, randomized, ascending dose, double-blind study. This study will be evaluating ascending doses of 50, 100, 200, and 400 mg of E6007. This study consists of 5 steps, 1 to 5. In steps 1 to 4 (at ascending doses of 50, 100, 200, and 400 mg), subjects will be randomly assigned in a 6:2 ratio (E6007: placebo) to receive single dose of the study drug under fasted condition. Following 3 days of washout period, subject will receive the study drug once daily for 7 days starting on the fifth day from the single dose administration. For step 3 (200 mg), subjects will subsequently have at least 17 days of washout period before being escalated to step 5 (200 mg) to receive single dose of E6007 under fed condition, to evaluate food effect of the study drug.

Full Title of Study: “A Phase 1 Single/ Multiple-Dose Study of E6007 in Healthy Japanese Male Subjects”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: July 2015

Interventions

  • Drug: E6007
  • Drug: E6007 matching placebo

Arms, Groups and Cohorts

  • Experimental: 50 mg E6007 fasted condition
    • E6007 50mg or E6007 matching placebo x 1, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
  • Experimental: 100 mg E6007 fasted condition
    • E6007 50mg or E6007 matching placebo x 2, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
  • Experimental: 200 mg E6007 fasted condition
    • E6007 50mg or E6007 matching placebo x 4, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
  • Experimental: 400 mg E6007 fasted condition
    • E6007 50mg or E6007 matching placebo x 8, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
  • Experimental: 200 mg E6007 fed condition
    • E6007 50mg or E6007 matching placebo x 4, orally once daily in the morning under fed condition. Drug administration on 1 day (Day 1).

Clinical Trial Outcome Measures

Primary Measures

  • Safety and tolerability of E6007 as a measure of Adverse events
    • Time Frame: Screening and up to 17 days after last administration of drug
  • Plasma E6007 concentration over time period – Cmax (maximum concentration)
    • Time Frame: Up to 15 days
  • Plasma E6007 concentration over time period – tmax (Time to achieve maximum concentration (Cmax))
    • Time Frame: Up to 15 days
  • Plasma E6007 concentration over time period – AUC (0-t) (Area Under the Curve (AUC) from Time Zero to Last Quantifiable Concentration)
    • Time Frame: Up to 15 days
  • Plasma E6007 concentration over time period – AUC (0-inf) (AUC extrapolated to infinity)
    • Time Frame: Up to 15 days
  • Plasma E6007 concentration over time period – t1/2 (Terminal phase half-life)
    • Time Frame: Up to 15 days
  • Plasma E6007 concentration over time period – CL/F (Apparent clearance)
    • Time Frame: Up to 15 days
  • Plasma E6007 concentration over time period – Vz/F (Apparent volume of distribution)
    • Time Frame: Up to 15 days
  • Plasma E6007 concentration over time period – Css,max (maximum steady state concentration)
    • Time Frame: Up to 15 days
  • Plasma E6007 concentration over time period – AUC (0-tau) (AUC from time zero to time tau over a dosing interval at steady state)
    • Time Frame: Up to 15 days

Secondary Measures

  • Dose proportionality under fasted conditions with Cmax, AUC (0-t), AUC(0-inf), Cssmax and AUC(0-t)
    • Time Frame: Up to 15 days
  • Geometric mean proportion (fed:fasted) of Cmax, AUC(0-t) and AUC(0-inf) for 200mg E6007 dose
    • Time Frame: Up to 5 days
  • Evaluate relationship between E6007 plasma concentrations and electrocardiogram (ECG) parameter (QTcF)
    • Time Frame: Up to 15 days

Participating in This Clinical Trial

Inclusion criteria Subjects must meet all of the following criteria to be included in this study: 1. Healthy Japanese male subjects aged 20 to 44 years at the time of informed consent. 2. Has voluntarily consented, in writing, to participate in this study. 3. Has been thoroughly briefed on the conditions for participation in the study, and is willing and able to comply with the conditions. Exclusion criteria Subjects who meet any of the following criteria will be excluded from this study: 1. Has a clinically significant medical condition requiring treatment within 8 weeks before the initial study drug administration, or a history of clinically significant infection requiring treatment within 4 weeks before the initial drug administration. 2. History of surgical treatment such as resection of the liver, kidney, or Gastrointestinal tract, that may affect the Pharmacokinetic profiles of study drugs. 3. Ineligible for study participation in the opinion of the investigator or sub-investigator.

Gender Eligibility: Male

Minimum Age: 20 Years

Maximum Age: 44 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Eisai Co., Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.